Participants will be asked to collect urine and dialysate the week before the first treatment and during the treatment days. In addition, blood samples will be collected before and during the treatment weeks in order to compare the effects of conventional PD with that of WEAKID treatment. A peritoneal equilibrium test will also be done before and after the treatment weeks to test the function of the lining of the abdomen (the peritoneal membrane). conditions: Renal Insufficiency, Chronic conditions: Kidney Failure, Chronic conditions: Chronic Kidney Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This study has a first-in-human, prospective, open-label, non-randomized, three-center, single-arm design. primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: WEAKID measure: Serious adverse device effects (SADEs) and device deficiencies (DDs) measure: Critical changes in blood pressure measure: Critical changes in heart rate measure: Critical changes in body temperature measure: Critical changes in oxygen saturation measure: Critical changes in plasma potassium measure: Critical changes in plasma calcium measure: Critical changes in plasma bicarbonate measure: Critical changes in intra-abdominal dialysate volume measure: Critical changes in intra-abdominal pressure measure: Adverse events (AEs) and device deficiencies (DDs) measure: Number of WEAKID treatments measure: Duration of WEAKID treatments measure: Dialysate flow rates during WEAKID treatment measure: Evolution of blood pressure measure: Evolution of heart rate measure: Evolution of body temperature measure: Evolution of oxygen saturation measure: Ultrafiltration volume measure: Peak glucose concentration in the device effluent measure: Ultrafiltration efficiency measure: Removal of urea by the WEAKID system measure: Removal of creatinine by the WEAKID system measure: Removal of phosphate by the WEAKID system measure: Removal of potassium by the WEAKID system measure: Removal of uric acid by the WEAKID system measure: Removal of beta-2 microglobulin by the WEAKID system measure: Removal of vitamin B12 by the WEAKID system measure: Mass transfer area coefficient of urea measure: Mass transfer area coefficient of creatinine measure: Mass transfer area coefficient of phosphate measure: Mass transfer area coefficient of potassium measure: Mass transfer area coefficient of uric acid measure: Mass transfer area coefficient of beta-2 microglobulin measure: Mass transfer area coefficient of vitamin B12 measure: Plasma clearance of urea measure: Plasma clearance of creatinine measure: Plasma clearance of phosphate measure: Plasma clearance of potassium measure: Plasma clearance of uric acid measure: Plasma clearance of beta-2 microglobulin measure: Plasma clearance of vitamin B12 measure: The plasma reduction ratio of the protein-bound uremic toxin p-cresyl sulfate measure: The plasma reduction ratio of the protein-bound uremic toxin p-cresyl glucuronide measure: The plasma reduction ratio of the protein-bound uremic toxin indole acetic acid measure: The plasma reduction ratio of the protein-bound uremic toxin kynurenine measure: The plasma reduction ratio of the protein-bound uremic toxin kynurenic acid measure: The plasma reduction ratio of the protein-bound uremic toxin hippuric acid measure: The release of base measure: Evolution of plasma levels of urea measure: Evolution of plasma levels of creatinine measure: Evolution of plasma levels of uric acid measure: Evolution of plasma levels of beta-2 microglobulin measure: Evolution of plasma levels of phosphate measure: Evolution of plasma levels of potassium measure: Evolution of plasma levels of bicarbonate measure: Evolution of plasma levels of lactate measure: Evolution of plasma levels of sodium measure: Evolution of plasma levels of chloride measure: Evolution of plasma levels of calcium measure: Evolution of plasma levels of magnesium measure: Evolution of plasma levels of glucose measure: Evolution of plasma levels of lactate dehydrogenase measure: Evolution of plasma levels of vitamin B12 measure: Evolution of plasma levels of albumin measure: Evolution of plasma leucocyte count measure: Evolution of plasma thrombocyte count measure: Evolution of plasma levels of C-reactive protein (CRP) measure: Evolution of plasma levels of bilirubin measure: Evolution of plasma levels of aspartate transaminase (ASAT) measure: Evolution of plasma levels of alanine aminotransferase (ALAT) measure: Evolution of sodium levels in dialysate effluent measure: Evolution of chloride levels in dialysate effluent measure: Evolution of calcium levels in dialysate effluent measure: Evolution of magnesium levels in dialysate effluent measure: Evolution of bicarbonate levels in dialysate effluent measure: Evolution of lactate levels in dialysate effluent measure: Evolution of pH of dialysate effluent measure: Total number of device deficiencies and adverse device effects measure: Evolution of delta intraperitoneal pressure during WEAKID treatment measure: Patient tolerance (abdominal discomfort) measure: Evolution of uremic symptoms measure: Usability measure: Baseline characteristics measure: Peritoneal equilibrium tests sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Università degli studi di Modena e Reggio Emilia (UNIMORE) status: NOT_YET_RECRUITING city: Modena zip: 41121 country: Italy name: Gabriele Donati, Prof., MD, PhD role: CONTACT phone: +39-0594225331 email: gabriele.donati@unimore.it name: Giulia Ligabue, MSc, PhD role: CONTACT phone: +39-0594224175 email: giulia.ligabue@unimore.it lat: 44.64783 lon: 10.92539 facility: University Medical Center Utrecht (UMCU) status: RECRUITING city: Utrecht zip: 3584 CX country: Netherlands name: Karin GF Gerritsen, MD, PhD role: CONTACT phone: +31-887557375 email: k.g.f.gerritsen@umcutrecht.nl name: Dian P Bolhuis, MSc role: CONTACT phone: +31-887557375 email: d.p.bolhuis-3@umcutrecht.nl lat: 52.09083 lon: 5.12222 facility: Hospital Universario La Paz (SERMAS) status: NOT_YET_RECRUITING city: Madrid zip: 28029 country: Spain name: Gloria del Peso Gilsanz, MD, PhD role: CONTACT phone: +34-913585339 email: gloria.delpeso@salud.madrid.org name: Maria A Bajo Rubio, MD, PhD role: CONTACT phone: +34-913585339 email: mauxiliadora.bajo@salud.madrid.org lat: 40.4165 lon: -3.70256 hasResults: False